This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis
Bone Marrow Transplantation Open Access 19 April 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Batts ED, Lazarus HM . Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007; 40: 709–719.
Ruutu T, Hermans J, Niederwieser D, Greatwhol A, Kiehl M, Volin L et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European group for blood and marrow transplantation (EBMT). Br J Haematol 2002; 118: 112–119.
George JN . Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927–1934.
Au W-Y, Ma ES, Lee T-L, Ha S-Y, Fung AT, Lie AKW et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 2007; 137: 475–478.
Gallerani E, Lerch E, Romagnani E, Stathis A, Giardelli G, Zwhalen H et al. Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab. Eur J Haematol 2006; 77: 527–529.
Yassa SK, Blessios G, Marinides G, Venuto RC . Anti-CD20 monoclonal antibody (Rituximab) for life-threatening haemolytic–uremic syndrome. Clin Transplant 2005; 19: 423–426.
Ostronoff N, Ostronoff F, Calixto R, Florencio R, Florencio M, Domingues MC et al. Life-threatening haemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplantation recipient. Bone Marrow Transplant 2007; 39: 649–651.
Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571–575.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carella, A., D'Arena, G., Greco, M. et al. Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 41, 1063–1065 (2008). https://doi.org/10.1038/bmt.2008.25
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.25
This article is cited by
-
Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis
Bone Marrow Transplantation (2021)
-
Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?
Bone Marrow Transplantation (2017)
-
Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis
Journal of Thrombosis and Thrombolysis (2012)
-
Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin
Bone Marrow Transplantation (2010)